keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/28087133/secukinumab-sustains-early-patient-reported-outcome-benefits-through-1%C3%A2-year-results-from-2-phase-iii-randomized-placebo-controlled-clinical-trials-comparing-secukinumab-with-etanercept
#1
Bruce Strober, Alice B Gottlieb, Bintu Sherif, Patrick Mollon, Isabelle Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, Charis Papavassilis, Mark G Lebwohl
BACKGROUND: Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment. OBJECTIVE: This analysis focused on the effect of secukinumab treatment on patient-reported health-related quality of life as assessed by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis. METHODS: The proportion of subjects achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response, and sustained DLQI score 0/1 response up to week 52 were compared between secukinumab and etanercept...
January 10, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28069297/lesions-on-the-back-of-hands-and-female-gender-predispose-to-stigmatization-in-patients-with-psoriasis
#2
Marlena Hawro, Marcus Maurer, Karsten Weller, Romuald Maleszka, Anna Zalewska-Janowska, Andrzej Kaszuba, Zofia Gerlicz-Kowalczuk, Tomasz Hawro
BACKGROUND: Psoriasis vulgaris is characterized by disfiguring and stigmatizing skin lesions. The links among lesions distribution, severity, and stigmatization remain unclear. OBJECTIVE: We sought to investigate if the involvement of visible and sensitive areas is linked to stigmatization. METHODS: In all, 115 patients with psoriasis vulgaris were assessed for disease severity, skin lesions distribution, itch, and stigmatization using the Feelings of Stigmatization Questionnaire...
January 6, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28064543/itolizumab-a-novel-anti-cd6-monoclonal-antibody-a-safe-and-efficacious-biologic-agent-for-management-of-psoriasis
#3
Sunil Dogra, Shraddha Uprety, Swaroop Hassan Suresh
Psoriasis, a chronic immune-mediated skin disorder is associated with significant physical, psychological, and quality of life impairments. Along with well-documented genetic and environmental factors, immunological factors also contribute to the pathogenesis of psoriasis. Among the immunological factors, CD6 - dependent T-cell proliferation to form Th1 and Th17 cells play a major role in the pathogenesis of psoriasis. Itolizumab is the first humanized IgG1 monoclonal antibody, which selectively targets CD6...
January 9, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28063525/the-impact-of-skin-diseases-on-quality-of-life-a-multicenter-study
#4
G Sanclemente, C Burgos, J Nova, F Hernández, C González, M I Reyes, N Córdoba, Á Arévalo, E Meléndez, J Colmenares, S Ariza, G Hernández
INTRODUCTION: To date, no formal study has been published regarding how Colombian patients with skin disorders could be affected according to their perception of disease. OBJECTIVE: To determine the impact in quality of life of skin diseases in a Colombian population. METHODS: This multicenter study included patients with skin disease from almost the whole country. Individuals >18 years old; of any gender; with any skin disease and who signed informed consent, were included...
January 4, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28057360/efficacy-and-safety-of-guselkumab-an-anti-interleukin-23-monoclonal-antibody-compared-with-adalimumab-for-the-continuous-treatment-of-patients-with-moderate-to-severe-psoriasis-results-from-the-phase-iii-double-blinded-placebo-and-active-comparator-controlled
#5
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Bruce Randazzo, Yasmine Wasfi, Yaung-Kaung Shen, Shu Li, Alexa B Kimball
BACKGROUND: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. OBJECTIVES: We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with psoriasis treated for 1 year. METHODS: Patients were randomized to guselkumab 100 mg (weeks 0 and 4, then every 8 weeks; n = 329); placebo→guselkumab (weeks 0, 4, and 12 then guselkumab at weeks 16 and 20, then every 8 weeks; n = 174); or adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47; n = 334)...
December 29, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28042711/the-impact-of-pasi-75-and-pasi-90-on-quality-of-life-in-moderate-to-severe-psoriasis-patients
#6
Michael Abrouk, M Nakamura, T H Zhu, B Farahnik, J Koo, T Bhutani
BACKGROUND: It is well known that psoriasis significantly impacts patients' quality of life (QoL). With the introduction of improved treatment modalities with biologic agents, more patients with moderate to severe psoriasis are able to achieve better results as measured by the Psoriasis Area and Severity Index (PASI). PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement. With newer biologic agents such as secukinumab, ixekizumab and brodalumab, patients are now capable of achieving PASI 90, introducing additional clinical decisions for physicians when considering treatment options...
December 31, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28032340/the-burden-of-common-skin-diseases-assessed-with-the-eq5d-a-european-multi-centre-study-in-13-countries
#7
F Balieva, J Kupfer, L Lien, U Gieler, A Y Finlay, L Tomas-Aragonés, F Poot, L Misery, F Sampogna, H van Middendorp, J A Halvorsen, J C Szepietowski, A Lvov, S E Marrón, M S Salek, F J Dalgard
BACKGROUND: Generic instruments measuring health related quality of life (HRQoL), like EQ5D, enable comparison of skin diseases with healthy populations and non-dermatological medical conditions, as well as calculation of utility data. OBJECTIVES: The aims were to measure HRQoL in patients with common skin diseases and healthy controls across Europe using the EQ5D. METHODS: This multi-center observational cross-sectional study was conducted in 13 European countries...
December 29, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/28025609/indications-for-tonsillectomy-stratified-by-the-level-of-evidence
#8
REVIEW
Jochen P Windfuhr
Background: One of the most significant clinical trials, demonstrating the efficacy of tonsillectomy (TE) for recurrent throat infection in severely affected children, was published in 1984. This systematic review was undertaken to compile various indications for TE as suggested in the literature after 1984 and to stratify the papers according to the current concept of evidence-based medicine. Material and methods: A systematic Medline research was performed using the key word of "tonsillectomy" in combination with different filters such as "systematic reviews", "meta-analysis", "English", "German", and "from 1984/01/01 to 2015/05/31"...
2016: GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery
https://www.readbyqxmd.com/read/28002334/gender-differences-among-patients-with-primary-ankylosing-spondylitis-and-spondylitis-associated-with-psoriasis-and-inflammatory-bowel-disease-in-an-iberoamerican-spondyloarthritis-cohort
#9
Margarita Landi, Hernán Maldonado-Ficco, Rodolfo Perez-Alamino, José A Maldonado-Cocco, Gustavo Citera, Pablo Arturi, Percival D Sampaio-Barros, Diana E Flores Alvarado, Rubén Burgos-Vargas, Elena Santos, Daniel Palleiro, Miguel A Gutiérrez, Elsa Vieyra-Sousa, Fernando Pimentel-Santos, Sergio O Paira, Alberto Berman, Claudia Vera Barrezueta, Janitzia Vazquez-Mellado, Eduardo Collantes-Estevez
The aim of the study was to compare clinical manifestations, disease activity, functional capacity, spinal mobility, and radiological findings between men and women from a multicenter, multiethnic Ibero-American cohort of patients with Spondyloarthritis (SpA).This observational cross-section study included 1264 consecutive SpA patients who fulfilled the modified New York criteria for ankylosing spondylitis (AS). Demographic, clinical, and radiologic data were evaluated. Categorical data were compared by X or Fisher's exact tests and continuous variables by ANOVA with post-hoc tests...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27995617/prevalence-of-alexithymia-in-patients-with-psoriasis-and-its-association-with-disease-burden-a-multicentre-observational-study
#10
F Sampogna, L Puig, P Spuls, G Girolomoni, M A Radtke, B Kirby, M Brunori, P Bergmans, P Smirnov, J Rundle, F Lavie, C Paul
BACKGROUND: Single-centre studies show that alexithymia, defined as difficulty in recognizing and describing emotions, is more prevalent among psoriasis patients than in the general population. However, its prevalence and the consequences of the association between alexithymia and psoriasis are unclear. OBJECTIVES: The primary objective of this study was to determine the prevalence of alexithymia, as defined by a score ≥61 in the 20-item Toronto Alexithymia Scale (TAS-20), in a large sample of patients who had plaque psoriasis for ≤10 years and were eligible for phototherapy or systemic treatment...
December 20, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27990382/general-measures-and-quality-of-life-issues-in-psoriasis
#11
Rashmi Sarkar, Shikha Chugh, Shivani Bansal
Psoriasis generally does not affect survival but has significant detrimental effect on quality of life (QOL), which may be comparable to that of ischemic heart disease, diabetes, depression, and cancer. The foremost important thing in the management of psoriasis is counseling of the patient. The clinician needs to be empathetic and spend adequate time with the patient and educating the patient about psoriasis. Clinicians should make it clear to the patient that the primary goal of treatment is control of the disease rather than cure...
November 2016: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/27983745/health-related-quality-of-life-in-children-and-adolescents-with-psoriasis-a-systematic-review-and-meta-analysis
#12
Hilde Randa, Tanja Todberg, Lone Skov, Lotte S Larsen, Robert Zachariae
Studies demonstrating the negative impact of paediatric psoriasis on health-related quality of life (HRQOL) are accumulating, but little is known about moderators of HRQOL. The objectives of this review were to summarize studies on HRQOL in paediatric psoriasis and to explore the potential moderating influences of demographic and clinical variables. Searches were conducted by 2 independent researchers in PubMed, Embase, CINAHL, PsycINFO, and Scopus for papers published between 1995 (the date the first dermatology-specific HRQOL-instrument for children was introduced) and 2016...
December 16, 2016: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/27976465/determination-of-the-nail-psoriasis-severity-index-improvement-rate-standards-for-nail-psoriasis-treatment-in-a-phase-iv-clinical-trial-of-ustekinumab-the-marcopolo-study
#13
LETTER
S W Youn, B R Kim, S Cho, S J Seo, E S Lee, J Y Roh, G S Choi, M G Lee
No abstract text is available yet for this article.
December 15, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27971893/the-impact-of-psoriasis-vulgaris-on-health-related-quality-of-life-in-greece
#14
Yfantopoulos, A Chantzaras, S Kontodimas
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27958625/genital-psoriasis-a-hidden-multidisciplinary-problem-a-review-of-literature
#15
Piotr Czuczwar, Anna Stępniak, Andy Goren, Wojciech Wrona, Tomasz Paszkowski, Mariola Pawlaczyk, Dorota Piekarska-Myślińska, Sławomir Woźniak, Aldona Pietrzak
Genital psoriasis is a variety of autoimmune dermatological disease - psoriasis with relapsing-remitting course, which can have an onset in all age groups. It is most often diagnosed at an advanced stage. Genital psoriasis is considered an embar-rassing condition and is often misjudged as a sexually transmitted disease or allergic reaction due to low social awareness of the disease. The manifestations of genital psoriasis may differ from typical genital dermatoses and with symptoms such as itch, erythroderma and vaginal discharge may mimic other diseases at an early stage...
2016: Ginekologia Polska
https://www.readbyqxmd.com/read/27943234/immune-related-alopecia-areata-and-universalis-type-in-cancer-patients-receiving-immune-checkpoint-inhibitors
#16
A Zarbo, V R Belum, V Sibaud, S Oudard, M A Postow, J J Hsieh, R J Motzer, K J Busam, M E Lacouture
CTLA-4, PD-1, and PD-L1 monoclonal antibodies, commonly known as immune checkpoint inhibitors, are used for the treatment of various malignancies. The mechanism of action involves the inhibition of negative regulators of immune activation, which results in many patients developing immune-related adverse events (irAEs) including endocrinopathies, pneumonitis, colitis, hepatitis and dermatologic events. Dermatologic irAEs include maculopapular rash, pruritus, vitiligo, blistering disorders, mucocutaneous lichenoid eruptions, rosacea, and exacerbation of psoriasis...
December 11, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27936972/fixed-combination-calcipotriol-plus-betamethasone-dipropionate-aerosol-foam-in-the-treatment-of-psoriasis-vulgaris-rationale-for-development-and-clinical-profile
#17
Carle Paul, Bo Bang, Mark Lebwohl
Psoriasis is a chronic, immune-mediated inflammatory disorder with a significant negative impact on quality of life. Most patients with mild-to-moderate psoriasis manage their disease with topical therapies; the most commonly used formulations contain corticosteroids and/or vitamin D3 analogues. However, adherence to topical treatment remains a significant issue as the daily treatment regimen can be cumbersome and time consuming and many patients do not obtain complete/almost complete clearance. Areas covered: Published pre-clinical and clinical data evaluating calcipotriol 50 µg/g (Cal) and betamethasone 0...
January 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27909086/the-12-item-psoriatic-arthritis-impact-of-disease-questionnaire-construct-validity-reliability-and-interpretability-in-a-clinical-setting
#18
Marco Di Carlo, Andrea Becciolini, Valentina Lato, Chiara Crotti, Ennio Giulio Favalli, Fausto Salaffi
OBJECTIVE: To study, in a real-life setting, the construct validity, the reliability, and the interpretability of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire in patients with psoriatic arthritis (PsA). METHODS: In 144 consecutive patients with PsA (81 men and 63 women, mean age of 51.4 ± 12.8 yrs, and 77 receiving biologic treatment), the PsAID-12 and other patient-reported outcomes (PRO) were collected, such as the Dermatology Life Quality Index...
December 1, 2016: Journal of Rheumatology
https://www.readbyqxmd.com/read/27908543/from-the-medical-board-of-the-national-psoriasis-foundation-treatment-targets-for-plaque-psoriasis
#19
April W Armstrong, Michael P Siegel, Jerry Bagel, Erin E Boh, Megan Buell, Kevin D Cooper, Kristina Callis Duffin, Lawrence F Eichenfield, Amit Garg, Joel M Gelfand, Alice B Gottlieb, John Y M Koo, Neil J Korman, Gerald G Krueger, Mark G Lebwohl, Craig L Leonardi, Arthur M Mandelin, M Alan Menter, Joseph F Merola, David M Pariser, Ronald B Prussick, Caitriona Ryan, Kara N Shah, Jeffrey M Weinberg, MaryJane O U Williams, Jashin J Wu, Paul S Yamauchi, Abby S Van Voorhees
BACKGROUND: An urgent need exists in the United States to establish treatment goals in psoriasis. OBJECTIVE: We aim to establish defined treatment targets toward which clinicians and patients with psoriasis can strive to inform treatment decisions, reduce disease burden, and improve outcomes in practice. METHODS: The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method. The process consisted of: (1) literature review, (2) pre-Delphi question selection and input from general dermatologists and patients, and (3) 4 Delphi rounds...
November 28, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27895471/adherence-satisfaction-and-preferences-for-treatment-in-patients-with-psoriasis-in-the-european-union-a-systematic-review-of-the-literature
#20
I Belinchón, R Rivera, C Blanch, M Comellas, L Lizán
BACKGROUND AND OBJECTIVE: Adherence to treatment in patients with psoriasis is often poor. An investigation of patient preferences and satisfaction with treatment may be important, based on the expected correlation with therapy compliance. This paper aims to examine and describe the current literature on patient preferences, satisfaction and adherence to treatment for psoriasis in the European Union (EU). METHODS: Electronic searches were conducted using PubMed, ISI Web of Knowledge, Scopus, Spanish databases and Google Scholar...
2016: Patient Preference and Adherence
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"